The expression of a new variant of the pro-apoptotic molecular Bax, Baxψ, is correlated with an increased survival of glioblastoma multiforme patients

Human Molecular Genetics

Volumn 11, Issue 6, 2002, Pages 675-687

  Cartron, Pierre François ^a   Oliver, Lisa ^a   Martin, Stéphane ^a,b   Moreau, Carole ^a   LeCabellec, Marie Thérèse ^a   Jezequel, Pascal ^c   Meflah, Khaled ^a   Vallette, François M ^a  

^a INSERM   (France)

^b CHU de Nantes   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; GENE DELETION; GENETIC CODE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MITOCHONDRION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METHYLATION; PROTEIN VARIANT; RNA TRANSCRIPTION; SURVIVAL TIME; TRANSGENE; TUMOR GROWTH; WILD TYPE;

ANIMALS; APOPTOSIS; BASE SEQUENCE; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; BRAIN NEOPLASMS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SEQUENCE HOMOLOGY, NUCLEIC ACID; SURVIVAL RATE;

MUS MUSCULUS;

EID: 0037087706     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. BCL-2 gene family and the regulation of programmed cell death
2. Mechanisms of apoptosis
3. Apoptosis and cancer
4. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
5. The Bcl-2 protein family: Arbiters of cell survival
6. Mitochondrial control of cell death
7. Bax suppresses tumorigenesis and stimulates apoptosis in vivo
8. Haploid loss of Bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: Reduction in protective apoptotic response at the preneoplastic stage
9. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution
10. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX
11. Role of BAX mutations in mismatch repair-deficient colorectal carcinogenesis
12. Tumor suppressor p53 is a direct transcription activator of the human Bax gene
13. Bax is a transcriptional target and mediator of c-myc-induced apoptosis
14. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
15. Histopathology, classification, and grading of gliomas
16. Glioma classification: A molecular reappraisal
17. Bax cleavage is mediated by calpain during drug-induced apoptosis
18. Regulated targeting of BAX to mitochondria
19. The C-terminus of Bax is not a membrane addressing/anchoring signal
20. BID-dependent and BID-independent pathways for BAX insertion into mitochondria
21. The BAX gene maps to the glioma candidate region at 19q13.3 but is not altered in human gliomas
22. Epigenetics: Regulation through repression
23. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer
24. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
25. The substitution of the C-terminus of Bax by that of Bcl-xl does not affect its subcellular localization but abrogates its pro-apoptotic properties
26. The challenge of p53 as prognostic and predictive factor in gliomas
27. Expression of Bcl-2, Bax and Bcl-xl in human gliomas: A re-appraisal
28. The N-end rule: Functions, mysteries, uses
29. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression
30. Translational pathophysiology: A novel mechanism of human disease
31. Bax kappa, a novel Bax splice variant from ischemic rat brain lacking an ART domain, promotes neuronal cell death
32. Role of BAX in the apoptotic response to anticancer agents